Seek Labs Unveils Investigational, Equipment-Free Molecular Prototype for MTB on Rapid-Deploy SeekIt™ Platform

13 August 2025

Salt Lake City, UT, August 13, 2025 — Seek Labs, a biotech company boldly seeking a healthier world through AI-powered discovery, programmable therapeutics, and point-of-care diagnostics, announced a significant advancement in the global fight against tuberculosis (TB) with an investigational prototype for Mycobacterium tuberculosis (MTB) detection on its SeekIt™ platform. In internal analytical testing, the MTB SeekIt test delivered accurate results in under 60 minutes. Importantly, this innovation addresses a key limitation that has historically hindered effective TB diagnostics: breaking apart MTB’s waxy, lipid-rich cell wall to gain access to detectable genetic material. In internal testing, SeekIt’s proprietary chemical lysis step achieved this in just 15 minutes without heat, mechanical disruption, or complex lab tools and skilled operators.

Seek Lab’s MTB test demonstrates the speed, adaptability, and field-readiness of the modular SeekIt platform. All SeekIt’s components – lysis chemistry, extraction, amplification, and detection – are proprietary to Seek Labs, exclusively discovered and developed in-house, and have been internally validated for performance and integration across multiple applications.

Read the full company press release here.

Source: Seek Labs